Latest Breaking News On - ரேட்திச் ஆய்வகங்கள் லிமிடெட் ப்ரைஸ் - Page 1 : comparemela.com

Dr. Reddy s (RDY) Ends Kuwait Study on Avigan for COVID-19 Zacks.com 1/28/2021 Shares of Dr. Reddy’s Laboratories Ltd. RDY fell 4.13% after it announced the termination of the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting. The study is being conducted in partnership with Global Response Aid FZCO (GRA). However, shares of Dr. Reddy’s have soared 48.2% in the past yearcompared with the industry’s growth of 11.9%. © Provided by Zacks.com The data from the Kuwait CVD-04-CD-001 study involving moderate-severe COVID-19 hospitalized patients did not show a statistically significant difference for the primary endpoint (i.e. time to sustained hypoxia resolution) for Aviganversus Placebo. The subgroup analysis of the low-risk study cohort (n=181) showed a 3-day earlier discharge in the Avigan group compared to the placebo group. The subgroup analysis data during the initial interim analysis showed that an antiviral drug

United statesReddys laboratories ltdModerna incEuropean commissionReddys laboratories ltd priceReddy laboratories ltdGlobal response aidNorth americaEli lillyZacks rankStrong buyஒன்றுபட்டது மாநிலங்களில்ரேட்திச் ஆய்வகங்கள் லிமிடெட்மாடர்னா இன்க்ஐரோப்பிய தரகுரேட்திச் ஆய்வகங்கள் லிமிடெட் ப்ரைஸ்